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progression was 5.0 months (95%CI: 1.8-8.1). In 22 patients 
with pain, a significant reduction of this symptom was 
recorded in terms of VAS (mean baseline VAS vs mean VAS at 
follow-up: 4.6 versus 3.1, p<0.001).  
 
Conclusion: Short-course accelerated H&N radiotherapy (20 
Gy in twice daily fractions for 2 consecutive days) is 
tolerated and effective in terms of symptom relief. A phase 
III comparison against a standard palliative regimen (30 Gy in 
10 fractions) has been planned in this patient population. 
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Purpose or Objective: To assess the effectiveness of a SHort-
course Accelerated RadiatiON therapy (SHARON) in the 
palliative treatment of patients with primary or secondary 
thoracic neoplasms, symptomatic, and not susceptible of 
surgery or radical radiotherapy. 
 
Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤3 and an expected 
survival > 3 months. Twenty-five patients were treated with 
radiotherapy (total dose: 20 Gy, 5 Gy per fraction) in 2 days 
with twice daily fractionation. The primary endpoint was to 
evaluate symptoms response rate. 
 
Results: Characteristics of the 25 enrolled patients were: 
male/female: 18/7; median age: 73 years (range: 46-93). 
ECOG performance status was <3 in 24 patients (96%). Two 
G1 skin (8%), 7 G1 haematological (28%) and 4 G1 pulmonary 
(16%) toxicities were recorded. No patient experienced G≥2 
acute toxicities. With a median follow-up time of 6 months 
(range, 1 to 16 months), of the 25 symptomatic patients, 24 
showed an improvement or resolution of baseline symptoms 
(overall palliative response rate: 96%). Three months overall 
survival was 87.5% (median survival time: 6 months; 95% CI 
5.3-6.6 mo). Median survival without symptoms progression 
was 3 months (95% CI:2.2-3.7mo). In 24 patients with pain, a 
significant reduction of this symptom was recorded in terms 
of VAS (5.0 vs 2.9, p=0.02). 
 
Conclusion: Short-course accelerated thorax radiotherapy 
(20 Gy in twice daily fractions, 2 consecutive days) is 
tolerated and effective in terms of symptom relief. A phase 
III comparison against a standard palliative regimen (30 Gy in 
10 fractions) has been planned in this patient population. 
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Purpose or Objective: Modern technologies of radiotherapy 
(SBRT,SABR) are utilized to treat patients with solitary spine 
metastases. Clinical studies have shown the efficacy of 
image-guided SBRT for pain control, local tumor control, as 
well as improvement of the life`s quality for these patients. 
In our clinic we have been using this method since 2013 for 
primary and re-irradiation treatment. 
 
Material and Methods: We have treated 32 pts (20 primary, 
12 reirradiation), 44 lesions. Eligible criteria were ECOG 1-2, 
spine metastases confirmed by MRI, the number of lesions 
were less than 3, adequate control of the primary tumor. 
Mean age 55.8 y.o. (47-72); gender distribution: 12 men and 
20 women. Option of the radiation dose and limit critical 
organs were installed according to the recommendations 
Elekta Spine Radiosurgery Research Consortium (ESRRC) and 
RTOG 0631. The prescribed dose was 12-24 Gy in 1-3 fr. For 
re-irradiation we have used the recommendations of Nieder 
et al.(2006): BED of each course - 98Gy, total BED -135.5Gy, 
the interval between two treatments was more than 6 
months. In these cases the prescribed dose was 20Gy in 5 fr. 
The procedure was performed by VMAT on a linear 
accelerator Elekta Synergy S, equipped with a 4-mm MLC, 
image-guided system (Elekta XVI), 6D robotic positioning 
system table (HexaPod). Overall duration of procedures was 
20-45 min. The follow-up was every 3 months from treatment 
time. It was assessed the pain intensity on a 10-point VAS, 
analgesics, performed MRI control. 
 
Results: Toxicity of SBRT was assessed by using CTC AE 
(v.4.0). Nausea gr.1 was observed in 3 (9.4%) pts, vomiting 
gr.1 - 1 (3.1%) pt. Toxicity gr.3-4 has not been observed. 
There were no cases of therapy interruption due to poor 
tolerability. Hematological toxicity during follow-up period 
was not revealed. In average of the period of 3 weeks all 
patients showed relief of pain syndrome with moderate (4-6 
points) to the minimum (1-3 points). The overall response to 
treatment (decrease of pain syndrome, local tumor control 
by MRI) was 90.6%, including a complete pain relief - 8 (25%) 
pts, stabilization - 21 (65.6%), lack of response to the 
treatment- 3 (9,4%). One patient had a pathological 
compression fracture of the vertebra at 4 months after 
irradiation, which required surgical intervention (installation 
of the fixing system). According to one patient`s MRI after 3 
month of treatment, we have revealed soft tissue component 
of tumor (MRI). 
 
Conclusion: SBRT was well tolerated. We did not observe any 
clinically significant toxicity. Reduction of the overall 
treatment time was comfortable for patients and increase 
capacity of LINAC. Further research is necessary to evaluate 
the efficacy and toxicity of the treatment and the 
development of criteria for the selection of patients. 
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Purpose or Objective: Many patients with advanced cancer 
develop bone metastases, with pain as a common, 
devastating consequence. Adequate treatment is important 
to maintain quality of life. Radiotherapy is the standard 
treatment for patients with painful bone metastases. Meta-
analyses of radiotherapy trials have consistently shown a pain 
response rate of approximately 60% implying that many 
patients are treated insufficiently. It would be worthwhile to 
identify patients who will not respond to radiotherapy as 
these patients might be candidates for other treatments. 
Furthermore, better understanding and identification of the 
patients who do not respond to radiation, might help in the 
development of innovative treatments as alternative or 
addition to standard (radiation) treatment options. We 
studied the relationship between patient and treatment 
characteristics and pain response in patients with metastatic 
bone disease, with the aim to construct a prediction model to 
guide individualized treatment decision-making. 
 
Material and Methods: We analyzed all prospectively 
collected data on pain response from a palliative 
radiotherapy clinic in an academic hospital. Patients were 
considered responders if they reported a decrease in pain 
score of at least 2 points with stable analgesic use within 3 
months after treatment. A multivariable logistic regression 
model was developed with age, gender, primary tumor, 
Karnofsky performance status (KPS), painful localization, 
presence of visceral metastases, previous systemic 
treatment, analgesic use at baseline, and baseline pain 
score. For variable selection, we started with the full model 
and applied backward stepwise selection with a selection 
criterion of p < 0.20. Performance of the model was 
quantified using the c-statistic and corrected for optimism. A 
worst case scenario (assuming no response in patients who 
were lost to follow up) was added as sensitivity analysis. 
 
Results: A total of 1018 patients treated between January 
1999 and November 2007 were included. Outcome was 
recorded in 588 (58%) patients, of which 394 (67%) reported a 
response. Primary tumor, KPS, baseline pain score, and 
analgesic use were predictive for response with a corrected 
c-statistic of 0.59 (Table). Assuming non-response in the 430 
patients without follow up (worst case scenario), there was 
still an association between response and primary tumor, 
KPS, and baseline pain score. 
 
Conclusion: Primary tumor, performance status, baseline 
pain score, and analgesic use are associated with pain 
response in patients with bone metastases. However, 
combining these factors in a prediction model showed poor 
discrimination limiting its use in clinical practice. Response 
rates after radiotherapy are moderate, and its prediction is 
difficult, which shows the need for development of 
innovative treatments for patients with bone metastases. 
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Purpose or Objective: To present the observed comparative 
advantages of the single fraction versus long course radiation 
therapy in the palliative treatment of bone metastasis, in the 
conditions of technological resources limited to one national 
center equipped with only cobalt machines.Purpose: To 
present the observed comparative advantages of the single 
fraction versus long course radiation therapy in the palliative 
treatment of bone metastasis, in the conditions of 
technological resources limited to one national center 
equipped with only cobalt machines. 
Material and Methods: The Radiation Therapy of Mother 
Theresa University Hospital Center, the unique public center 
providing RT in the country, performed a study comparing 
single dose of 8 Gy/1fr. versus 20 Gy/5fr. and 30gy/10fr. 
enrolling 110 patients during a time period of five years (2007 
– 2012). Factors for the treatment choice between available 
options were age, pain level, effect of narcotics and need for 
assistance as well as time and cost effectiveness. Pain relief 
was assessed based on the patient perception expressed 
during the follow up visits, 2 weeks, 4 weeks and 12 weeks 
after the treatment and subsequently every 12 weeks for a 
period of 48 weeks. Qualitative data from the follow up visits 
were classified in a scale of 10 points. 
 
Results: The complete pain relief was attained for 90 
patients or 81.8% out of 110 patients, subject to this study. 
From this number, 33 patients were treated with single shot, 
31 with 20 Gy/5 fraction and 46 with 30Gy/10fr. The 
percentage of patients benefiting partial pain relief varied 
from 17.4 to 19.5 which indicate also similar results from the 
available treatment regimes. Therefore, it wasn’t evidenced 
significant difference between the treatment options as 
regard to the patients achieving complete or partial pain 
relief. Further, the toxicity level scored 2-3 grade for all the 
treatment regimes used. In addition, the patients 
demonstrated similar median survival from 8 to 10 months for 
the three options. 
 
Conclusion: The findings of the study indicate that single 
fraction 800cGy/1fr is a treatment option with similar effects 
with the multiple fractions 20Gy/5fr and 30Gy/10fr. It can be 
used as more time and cost effective standard treatment 
especially for patients presenting higher level of pain and 
more in need for assistance including elder and those more 
distant from the treatment centers. 
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Purpose or Objective: To assess the efficacy of a SHort-
course Accelerated RadiatiON therapy (SHARON) regimen in 
the palliative treatment of complicated bone metastases. 
